Paper Details

  1. Home
  2. Paper Details

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial.

Author: BlumenfeldAndrew M, CreutzLela, DodickDavid, GandhiPranav, LiYe, LiptonRichard B, Pozo-RosichPatricia, SevertLawrence, StokesJonathan T

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Atogepant, an oral calcitonin gene-related peptide receptor antagonist, demonstrated significant improvements in patient-reported outcomes, including Migraine-Specific Quality-of-Life Questionnaire (MSQ) Role Function-Restrictive (RFR) scores and both Activity Impairment in Migraine-Diary (AIM-D) domains.
Paper Details　
Original Abstract of the Article :
BACKGROUND AND OBJECTIVES: The oral calcitonin gene-related peptide receptor antagonist atogepant is indicated for the preventive treatment of episodic migraine. We evaluated changes in patient-reported outcomes with atogepant in adults with migraine. METHODS: In this phase 3, 12-week, multicenter,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984220/

データ提供：米国国立医学図書館（NLM）

A New Oasis in the Desert of Migraine Treatment

Migraine, a debilitating headache disorder, often leaves sufferers feeling lost in a desert of pain. This research, like a beacon of hope, focuses on a new treatment option – atogepant – for the prevention of migraine headaches.

The study, conducted in a double-blind, placebo-controlled trial, evaluates the impact of atogepant on patient-reported outcomes in individuals experiencing 4-14 migraine days per month. The researchers meticulously analyzed data on various aspects of migraine impact, including quality of life, activity impairment, and headache intensity, ultimately demonstrating the potential of atogepant in mitigating migraine-related suffering.

A Ray of Hope for Migraine Sufferers

The study provides evidence suggesting that atogepant, a calcitonin gene-related peptide receptor antagonist, can significantly improve patient-reported outcomes related to migraine, including quality of life, activity impairment, and headache intensity. The findings suggest that atogepant may be a valuable addition to the arsenal of migraine prevention treatments.

Navigating the Migraine Desert

Understanding the specific needs and preferences of each individual struggling with migraine is crucial. This research serves as a guide for those seeking effective treatment options, highlighting the potential benefits of atogepant in improving quality of life and reducing migraine frequency.

Dr. Camel's Conclusion

This study offers a promising glimpse into the future of migraine treatment, suggesting that atogepant may provide a much-needed oasis for those navigating the desert of chronic migraine headaches. It underscores the importance of individualized treatment approaches in addressing the diverse needs of migraine sufferers.

Date :
  1. Date Completed 2023-02-23
  2. Date Revised 2023-03-06
Further Info :

Pubmed ID

36396451

DOI: Digital Object Identifier

PMC9984220

Related Literature

Article Analysis
・Effects of atogepant
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.